| Identification | Back Directory | [Name]
NEO214 | [CAS]
1361198-80-2 | [Synonyms]
NEO214
1-Pyrrolidinecarboxylic acid, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-oxo-, [(4S)-4-(1-methylethenyl)-1-cyclohexen-1-yl]methyl ester | [Molecular Formula]
C27H35NO5 | [MOL File]
1361198-80-2.mol | [Molecular Weight]
453.57 |
| Chemical Properties | Back Directory | [Boiling point ]
602.8±55.0 °C(Predicted) | [density ]
1.162±0.06 g/cm3(Predicted) | [form ]
Oil | [pka]
-2.89±0.40(Predicted) | [color ]
Colorless to off-white |
| Hazard Information | Back Directory | [Uses]
NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma[1]. | [References]
[1] Ou M, et al. Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate. Autophagy. 2023 Dec;19(12):3169-3188. DOI:10.1080/15548627.2023.2242696 |
|
|